EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 184 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $931,000 | -17.8% | 22,300 | -8.4% | 0.00% | 0.0% |
Q4 2020 | $1,133,000 | +7.4% | 24,334 | -2.0% | 0.00% | 0.0% |
Q3 2020 | $1,055,000 | -11.6% | 24,834 | -0.2% | 0.00% | 0.0% |
Q2 2020 | $1,194,000 | +26.1% | 24,892 | +21.0% | 0.00% | 0.0% |
Q1 2020 | $947,000 | -72.0% | 20,579 | -63.4% | 0.00% | -66.7% |
Q4 2019 | $3,381,000 | +1125.0% | 56,274 | +1053.4% | 0.00% | – |
Q3 2019 | $276,000 | +34.0% | 4,879 | +64.3% | 0.00% | – |
Q3 2018 | $206,000 | -1.0% | 2,970 | +7.8% | 0.00% | – |
Q2 2018 | $208,000 | -40.2% | 2,754 | -68.0% | 0.00% | -100.0% |
Q1 2016 | $348,000 | -68.6% | 8,600 | -31.2% | 0.00% | -50.0% |
Q4 2015 | $1,108,000 | -20.8% | 12,500 | -33.9% | 0.00% | 0.0% |
Q3 2015 | $1,399,000 | +72.9% | 18,900 | +89.0% | 0.00% | +100.0% |
Q2 2015 | $809,000 | – | 10,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |